Compass Financial Group INC SD Invests $172,000 in Integra LifeSciences Holdings Corporation $IART

Compass Financial Group INC SD acquired a new position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) in the 2nd quarter, Holdings Channel.com reports. The fund acquired 14,043 shares of the life sciences company’s stock, valued at approximately $172,000.

Several other large investors also recently made changes to their positions in IART. MassMutual Private Wealth & Trust FSB increased its position in shares of Integra LifeSciences by 6,017.6% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 10,094 shares of the life sciences company’s stock worth $124,000 after acquiring an additional 9,929 shares in the last quarter. CWM LLC increased its position in shares of Integra LifeSciences by 413.8% during the first quarter. CWM LLC now owns 6,664 shares of the life sciences company’s stock worth $147,000 after acquiring an additional 5,367 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its position in Integra LifeSciences by 16.9% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 13,352 shares of the life sciences company’s stock valued at $180,000 after purchasing an additional 1,927 shares in the last quarter. Teacher Retirement System of Texas bought a new position in Integra LifeSciences in the first quarter valued at $223,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Integra LifeSciences in the first quarter valued at $277,000. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

NASDAQ IART opened at $14.80 on Friday. The firm has a 50-day moving average of $14.19 and a 200-day moving average of $14.61. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23. The stock has a market cap of $1.15 billion, a PE ratio of -2.27 and a beta of 1.21. Integra LifeSciences Holdings Corporation has a 52-week low of $11.06 and a 52-week high of $27.13.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.02. The company had revenue of $415.61 million during the quarter, compared to analysts’ expectations of $395.06 million. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. Integra LifeSciences’s quarterly revenue was down .6% compared to the same quarter last year. During the same quarter last year, the company posted $0.63 EPS. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. On average, sell-side analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Integra LifeSciences in a research report on Saturday, September 27th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat.com, Integra LifeSciences has a consensus rating of “Reduce” and a consensus target price of $18.43.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.